These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 8911750)

  • 1. Irinotecan (CPT-11): a brief overview.
    Rivory LP
    Clin Exp Pharmacol Physiol; 1996; 23(10-11):1000-4. PubMed ID: 8911750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of CPT-11. Impact on activity.
    Rivory LP
    Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
    Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
    Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology of camptothecin and its derivatives].
    Rivory LP; Robert J
    Bull Cancer; 1995 Apr; 82(4):265-85. PubMed ID: 10846537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of CPT-11 and its active metabolite SN-38.
    Lavelle F; Bissery MC; André S; Roquet F; Riou JF
    Semin Oncol; 1996 Feb; 23(1 Suppl 3):11-20. PubMed ID: 8633248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Camptothecin analogues with enhanced antitumor activity at acidic pH.
    Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
    Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan.
    Mathijssen RH; Loos WJ; Verweij J; Sparreboom A
    Curr Cancer Drug Targets; 2002 Jun; 2(2):103-23. PubMed ID: 12188913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma pharmacokinetics of 7-ethyl-10-hydroxycamptothecin (SN-38) after intravenous administration of SN-38 and irinotecan (CPT-11) to rats.
    Kaneda N; Hosokawa Y; Yokokura T; Awazu S
    Biol Pharm Bull; 1997 Sep; 20(9):992-6. PubMed ID: 9331983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of irinotecan disposition and toxicity: a review.
    Fujita K; Sparreboom A
    Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38.
    Sadzuka Y; Hirotsu S; Hirota S
    Jpn J Cancer Res; 1999 Feb; 90(2):226-32. PubMed ID: 10189894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
    Haaz MC; Rivory LP; Riché C; Robert J
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.
    Bissery MC; Vrignaud P; Lavelle F; Chabot GG
    Anticancer Drugs; 1996 Jun; 7(4):437-60. PubMed ID: 8826613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
    Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
    Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status of camptothecin analogues as antitumor agents.
    Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
    J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of irinotecan.
    Robert J; Rivory L
    Drugs Today (Barc); 1998 Sep; 34(9):777-803. PubMed ID: 14988754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
    Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
    Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients.
    Rivory LP; Chatelut E; Canal P; Mathieu-Boué A; Robert J
    Cancer Res; 1994 Dec; 54(24):6330-3. PubMed ID: 7987823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of prolonged-release CPT-11-loaded microspheres in rats.
    Machida Y; Onishi H; Kurita A; Hata H; Morikawa A; Machida Y
    J Control Release; 2000 May; 66(2-3):159-75. PubMed ID: 10742577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.